MRNS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRNS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Marinus Pharmaceuticals's adjusted revenue per share for the three months ended in Sep. 2024 was $0.149. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.54 for the trailing ten years ended in Sep. 2024.
During the past 12 months, Marinus Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2025-05-13), Marinus Pharmaceuticals's current stock price is $0.55. Marinus Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $0.54. Marinus Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 1.02.
During the past 12 years, the highest Cyclically Adjusted PS Ratio of Marinus Pharmaceuticals was 21.29. The lowest was 0.43. And the median was 12.58.
The historical data trend for Marinus Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.52 | 0.52 | 0.53 | 0.53 | 0.54 |
For the Biotechnology subindustry, Marinus Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Marinus Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Marinus Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Marinus Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2024 (Change) | * | Current CPI (Sep. 2024) |
= | 0.149 | / | 133.0289 | * | 133.0289 | |
= | 0.149 |
Current CPI (Sep. 2024) = 133.0289.
Marinus Pharmaceuticals Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 0.000 | 102.862 | 0.000 |
201706 | 0.000 | 103.349 | 0.000 |
201709 | 0.000 | 104.136 | 0.000 |
201712 | 0.000 | 104.011 | 0.000 |
201803 | 0.000 | 105.290 | 0.000 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | 0.000 | 106.507 | 0.000 |
201812 | 0.000 | 105.998 | 0.000 |
201903 | 0.000 | 107.251 | 0.000 |
201906 | 0.000 | 108.070 | 0.000 |
201909 | 0.000 | 108.329 | 0.000 |
201912 | 0.000 | 108.420 | 0.000 |
202003 | 0.000 | 108.902 | 0.000 |
202006 | 0.000 | 108.767 | 0.000 |
202009 | 0.006 | 109.815 | 0.007 |
202012 | 0.049 | 109.897 | 0.059 |
202103 | 0.049 | 111.754 | 0.058 |
202106 | 0.052 | 114.631 | 0.060 |
202109 | 0.275 | 115.734 | 0.316 |
202112 | 0.041 | 117.630 | 0.046 |
202203 | 0.385 | 121.301 | 0.422 |
202206 | 0.048 | 125.017 | 0.051 |
202209 | 0.062 | 125.227 | 0.066 |
202212 | 0.159 | 125.222 | 0.169 |
202303 | 0.201 | 127.348 | 0.210 |
202306 | 0.116 | 128.729 | 0.120 |
202309 | 0.136 | 129.860 | 0.139 |
202312 | 0.127 | 129.419 | 0.131 |
202403 | 0.135 | 131.776 | 0.136 |
202406 | 0.141 | 132.554 | 0.142 |
202409 | 0.149 | 133.029 | 0.149 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Marinus Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 0.55 | / | 0.54 | |
= | 1.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 12 years, the highest Cyclically Adjusted PS Ratio of Marinus Pharmaceuticals was 21.29. The lowest was 0.43. And the median was 12.58.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of Marinus Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Elan Ezickson | director | AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139 |
Marvin Johnson | director | C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087 |
Scott Braunstein | director | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Christina Shafer | officer: Chief Commercial Officer | 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087 |
Martha E Manning | officer: VP, Gen. Counsel & Corp. Sec. | 700 PENNSYLVANIA DR, EXTON PA 19341 |
Joseph Hulihan | officer: Chief Medical Officer | 5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
Steven Pfanstiel | officer: CFO | 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Charles Austin | director | 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
Christine Berni Silverstein | director | C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Santiago Arroyo | director | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Sara Nochur | director | 295 WOODCLIFF RD, NEWTON MA 02461 |
Nicole Vitullo | director, 10 percent owner | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
Edward F Smith | officer: Chief Financial Officer | C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104 |
From GuruFocus
By Business Wire • 01-07-2025
By Business Wire • 08-13-2024
By GuruFocus Research • 08-14-2024
By GuruFocus News • 01-31-2025
By Business Wire • 11-12-2024
By Business Wire • 08-19-2024
By Marketwired • 08-05-2024
By Business Wire • 10-24-2024